55
Participants
Start Date
March 9, 2018
Primary Completion Date
November 10, 2022
Study Completion Date
November 10, 2022
obinutuzumab
Obinutuzumab 1000 mg solution used for infusion according to routine clinical practice.
The Catholic University of Korea Seoul St. Mary's Hospital, Seoul
St. Vincent's Hospital, Gyeonggi-do
Gachon University Gil Medical Center, Incheon
Inje University Busan Paik Hospital; Hematology-oncology, Busan
Pusan National University Hospital, Busan
Hallym University Sacred Heart Hospital; Department of Hematology, Gyeonggi-do
Catholic Univ. of Incheon St.Mary's Hospital; Hemato-oncology, Incheon
Kyung Hee University Hospital, Seoul
Korea University Anam Hospital, Seoul
Seoul National University Hospital, Seoul
Seoul St Mary's Hospital, Seoul
ChungAng University Hospital, Seoul
Borame Medical Center, Seoul
Yeouido St. Mary's Hospital, Seoul
Korea University Guro Hospital, Seoul
Samsung Medical Center, Seoul
Yonsei University Wonju Severance Christian Hospital, Wŏnju
Hoffmann-La Roche
INDUSTRY